#trump #rfkjr #bigpharma #pfizer #elililly #phrma #corruption
It was a matter of time ,Trump though talk in public but soft in reality , Trump and Kennedy had dinner with big pharma but consumer advocates were not invited, go figure.
#TrumpCoup #TreasuryTakeover #Musk
UPDATE
*#BusinessInsider has procured a list of the (so far) 30 people working for #CoPresident #Musk's #DOGE*
(14/n)
... who #Musk hired as an advisor over the summer to help his get-out-the-vote work, was most recently a senior political advisor at #PhRMA, a trade association that advocates on behalf of pharmaceutical companies. He was previously a national field director for the #RepublicanNationalCommittee
#trump #rfkjr #bigpharma #pfizer #elililly #phrma #corruption
It was a matter of time ,Trump though talk in public but soft in reality , Trump and Kennedy had dinner with big pharma but consumer advocates were not invited, go figure.
Today, the National Infusion Center Association (NICA), the Global Colon Cancer Association (GCCA) and the Pharmaceutical Research and Manufacturers of America (PhRMA) filed a complaint in U.S. District Court for the Western District of Texas asserting the price setting provisions in the Inflation Reduction Act are unconstitutional.
A broad diversity of patient advocacy groups have expressed alarm at Judge Kacsmaryk's unprecedented decision
“The implications of this ruling go far beyond #mifepristone,” read a statement of opposition signed by 30 organizations representing those with serious health conditions.
They warned, “If this judge’s ruling is allowed to stand, patients may no longer have the security of knowing that determinations about drug safety ultimately lie with the experts.”
Also objecting are pharmaceutical companies that recognize the threat to innovation posed by arbitrary judicial orders.
The interim director of the biotech organization #BIO described the decision as **an assault on science**, while the pharmaceutical organization #PhRMA expressed **serious concerns with any court substituting its opinion for the FDA’s expert approval decision-making**